Twin Focus Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Twin Focus Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,000	Closed	-$102K	–	167
2019 Q2	$102K	Sell	11,000 -9,000	-45%	-$109K	0.04%	142
2019 Q1	$314K	Hold	20,000	–	–	0.15%	79
2018 Q4	$308K	Buy	20,000 +5,000	+33%	+$103K	0.14%	74
2018 Q3	$323K	Hold	15,000	–	–	0.17%	70
2018 Q2	$365K	Sell	15,000 -5,000	-25%	-$102K	0.19%	66
2018 Q1	$342K	Buy	+20,000	New	+$390K	0.17%	68

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Twin Focus Capital Partners's TEVA Position: Q3 2019 in Review

Twin Focus Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 11,000 shares — an estimated $102K sold.

Twin Focus Capital Partners first reported a position in TEVA in Q1 2018 and held it in 6 quarters. The position peaked at $365K in Q2 2018. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

Twin Focus Capital Partners reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Twin Focus Capital Partners sold 11,000 Teva Pharmaceuticals shares in Q3 2019, an estimated $102K.
Twin Focus Capital Partners first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Twin Focus Capital Partners's Teva Pharmaceuticals position peaked at $365K in Q2 2018.
427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Twin Focus Capital Partners's 13F filing for Q3 2019, filed 7 Nov 2019.